Medical Simulation News
-
VeriSIM Life Secures a Federal Grant to Create a Drug Combinatorial Platform Against COVID-19
VeriSIM Life has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $255,908 to conduct research and development (R&D) work on rapid repurposing and translation of approved and investigational drugs for COVID-19 using its patented artificial intelligence (AI) driven biosimulation platform, BIOiSIM. VeriSIM Life has developed a whole-body ...
By VeriSIM Life
-
Transpara breast AI; strong clinical evidence evolves into real life screening use
The Transpara AI breast care solution, now being used in over 30 countries worldwide to find breast cancers faster and earlier, has 'remarkable potential' to reduce Radiologists' workload, according to a leading research team in Spain. The team at the renowned University Hospital Reina Sofia in Cordoba, has launched a world first prospective 2D AND 3D study to see how they could help ...
-
Medical Microinstruments Launches New Simulator for Robotic Microsurgery
PISA, Italy, May 26,2022 - Medical Microinstruments (MMI) SpA. a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the launch of its Symani Surgical System Simulator developed by VirtaMed. The simulator will improve, expand, and digitize the pathways for Symani training as surgeons prepare to expand their microsurgical skills through ...
-
CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan`s Top Pharmaceutical Companies
TOKYO and TEL AVIV, Israel, Sept. 30, 2021 /PRNewswire/ -- CytoReason, an AI company developing computational disease models for discovery and clinical drug development, and Summit Pharmaceuticals International (SPI), a Japanese company providing service and products to the pharmaceutical industry (wholly-owned subsidiary of Sumitomo Corporation), today announced that CytoReason has entered the ...
By CytoReason
-
Accenture HealthTech Innovation Challenge Names Eight Finalists
Accenture (NYSE: ACN) has named eight companies as finalists in the Accenture HealthTech Innovation Challenge, which brings together leading-edge startups with prominent health companies to tackle some of North America’s greatest health challenges. Attracting more than 2,600 startup applicants in the past five years, the Accenture HealthTech Innovation Challenge supports finding innovative ...
-
CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms
TEL AVIV, Israel, June 17, 2021 /PRNewswire/ -- CytoReason, an AI company developing a computational disease model of the human body for clinical drug development, today announced the initiation of a project with French global biopharmaceutical company Sanofi, which will utilize its cell-centered models and deconvolution techniques to suggest mechanistic insights for each asthma endotype. The ...
By CytoReason
-
CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology
TEL AVIV, Israel, May 19, 2021 /PRNewswire/ -- CytoReason, an Israeli company developing a computational model of the human body for faster drug discovery and development, today announced a collaboration with Swiss multinational biopharmaceutical company, Ferring Pharmaceuticals, which aims to establish new treatment options for patients with inflammatory bowel disease (IBD). This is the first ...
By CytoReason
-
Longenesis announces Longenesis.Immersive in collaboration with VR industry experts to offer subsidized pilots with hospitals
The ever-evolving and unprecedented COVID-19 situation exhibits extreme conditions in a variety of industries, including healthcare. It is a great challenge, in times of a healthcare system’s full devotion to the COVID-19 crisis, to sustain the same accessibility of healthcare services to everyone in need and preserving their high quality. Now, the use of emerging technologies such as VR/AR ...
By Longenesis
-
ASTM F2346 - 05(2011) Standard Test Methods for Static and Dynamic Characterization of Spinal Artificial Discs
Artificial intervertebral discs are orthopaedic implants that replace degenerated natural intervertebral discs. Their function is to support the anterior column of the spine while allowing motion at the operated level. These test methods outline materials and methods for the characterization of the mechanical performance of different artificial intervertebral discs ...
-
ASTM F2267 - 04(2011) Standard Test Method for Measuring Load Induced Subsidence of Intervertebral Body Fusion Device Under Static Axial Compression
Intervertebral body fusion devices are generally simple geometric shaped devices, which are often porous or hollow in nature. Their function is to support the anterior column of the spine to facilitate arthrodesis of the motion segment. This test method is designed to quantify the subsidence characteristics of different designs of intervertebral body fusion devices since ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you